Sandra Wear

1.5k total citations
7 papers, 276 citations indexed

About

Sandra Wear is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Sandra Wear has authored 7 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 6 papers in Molecular Biology and 2 papers in Genetics. Recurrent topics in Sandra Wear's work include Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (5 papers) and Ubiquitin and proteasome pathways (2 papers). Sandra Wear is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (5 papers) and Ubiquitin and proteasome pathways (2 papers). Sandra Wear collaborates with scholars based in United States, Canada and Australia. Sandra Wear's co-authors include Sundar Jagannath, Andrzej Jakubowiak, David S. Siegel, Alvin Wong, Robert Z. Orlowski, Ravi Vij, Nizar J. Bahlis, Lori Kunkel, Alexander K. Stewart and Michael Wang and has published in prestigious journals such as Blood and British Journal of Haematology.

In The Last Decade

Sandra Wear

7 papers receiving 267 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra Wear United States	7	245	236	107	20	9	7	276
Petra H.M. Westveer Netherlands	6	144 0.6×	198 0.8×	92 0.9×	19 0.9×	13 1.4×	8	212
Eli Gabayan United States	4	269 1.1×	295 1.3×	188 1.8×	21 1.1×	4 0.4×	6	343
Olga Samoilova United States	2	250 1.0×	296 1.3×	192 1.8×	30 1.5×	6 0.7×	2	313
C. Hulin France	6	141 0.6×	161 0.7×	92 0.9×	20 1.0×	4 0.4×	16	188
Pia Sondergeld Germany	4	139 0.6×	220 0.9×	135 1.3×	40 2.0×	17 1.9×	4	252
Maria Soroka‐Wojtaszko Poland	6	111 0.5×	133 0.6×	78 0.7×	23 1.1×	5 0.6×	12	154
Adrienne Briggs United States	5	142 0.6×	191 0.8×	118 1.1×	21 1.1×	12 1.3×	8	214
S Caltagirone Italy	5	219 0.9×	230 1.0×	123 1.1×	15 0.8×	7 0.8×	11	251
Ravi Vij United States	4	117 0.5×	137 0.6×	60 0.6×	11 0.6×	9 1.0×	13	171
Sara Bringhen Italy	4	97 0.4×	142 0.6×	77 0.7×	11 0.6×	9 1.0×	5	149

Countries citing papers authored by Sandra Wear

Since Specialization

Citations

This map shows the geographic impact of Sandra Wear's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Wear with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Wear more than expected).

Fields of papers citing papers by Sandra Wear

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Wear. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Wear. The network helps show where Sandra Wear may publish in the future.

Co-authorship network of co-authors of Sandra Wear

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Wear. A scholar is included among the top collaborators of Sandra Wear based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Wear. Sandra Wear is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Vij, Ravi, David S. Siegel, Sundar Jagannath, et al.. (2012). An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. British Journal of Haematology. 158(6). 739–748. 143 indexed citations

2.

Jakubowiak, Andrzej, Dominik Dytfeld, Sundar Jagannath, et al.. (2011). Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). Blood. 118(21). 631–631. 18 indexed citations

3.

Richardson, Paul G., Andrew Spencer, Paul Cannell, et al.. (2011). Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood. 118(21). 302–302. 53 indexed citations

4.

Siegel, David S., Meletios Α. Dimopoulos, Sung‐Soo Yoon, et al.. (2011). Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. Blood. 118(21). 480–480. 36 indexed citations

5.

Vij, Ravi, Jonathan L. Kaufman, Andrzej Jakubowiak, et al.. (2011). Final Results From the Bortezomib-naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM. Blood. 118(21). 813–813. 9 indexed citations

6.

Jakubowiak, Andrzej, David S. Siegel, Seema Singhal, et al.. (2011). Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. Blood. 118(21). 1875–1875. 7 indexed citations

7.

Richardson, Paul G., Craig C. Hofmeister, Todd M. Zimmerman, et al.. (2008). Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma. Blood. 112(11). 2770–2770. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact